Clinical Trial: A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816380) titled 'A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Sept. 07.

Brief Summary: This is a randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of JYP0322 compared with crizotinib in previously untreated ROS1-positive locally advanced or metastatic non-small cell lung cancer.

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)

Intervention: DRUG: JYP0322 Tablets

Oral administration, 150 mg each dose, three time...